Caption Management’s Zevra Therapeutics ZVRA Stock Holding History

Caption Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.7M	Buy	2,002,800 +901,600	+82%	+$8.13M	0.11%	200
2025 Q4	$9.87M	Buy	1,101,200 +101,100	+10%	+$956K	0.07%	339
2025 Q3	$9.51M	Buy	1,000,100 +900,100	+900%	+$9.03M	0.07%	295
2025 Q2	$881K	Hold	100,000	–	–	0.01%	969
2025 Q1	$749K	Buy	+100,000	New	+$795K	0.01%	998
2022 Q4	–	Sell	-50,000	Closed	-$313K	–	1793
2022 Q3	$313K	Buy	+50,000	New	+$283K	﹤0.01%	1174
2022 Q2	–	Sell	-42,500	Closed	-$214K	–	1909
2022 Q1	$214K	Buy	+42,500	New	+$270K	﹤0.01%	1265

Other funds holding ZVRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Caption Management's ZVRA Position: Q1 2026 in Review

Caption Management reduced its Zevra Therapeutics (ZVRA) stake by 53% in Q1 2026, selling an estimated $2.57M and leaving 255,236 shares worth $2.38M. The position accounts for 0.01% of the portfolio, ranked #777.

Caption Management first reported a position in ZVRA in Q4 2021 and has held it in 8 quarters since. The position peaked at $4.85M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

Caption Management held 255,236 shares of Zevra Therapeutics worth $2.38M as of Q1 2026.
Caption Management sold 284,876 Zevra Therapeutics shares in Q1 2026, an estimated $2.57M.
Zevra Therapeutics made up 0.01% of Caption Management's portfolio in Q1 2026, its #777 holding.
Caption Management first reported a position in Zevra Therapeutics in Q4 2021 and has held it in 8 quarters since.
Caption Management's Zevra Therapeutics position peaked at $4.85M in Q3 2025.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.